Elicera Therapeutics AB (SE:ELIC)

:ELIC

ELIC

Elicera Therapeutics AB

RESEARCH TOOLSreports

Want to see SE:ELIC full AI Analyst Report?

Elicera Therapeutics AB (ELIC) Price & Analysis

3 Followers

ELIC Stock Chart & Stats

kr5.35

kr0.03(1.27%)

At close: Mar 06 4:00 PM EST

kr5.35

kr0.03(1.27%)

Day’s Range― - ―

52-Week Rangekr2.26 - kr8.21

Previous CloseN/A

Volume204.65K

Average Volume (3M)134.24K

Market Cap

kr180.55M

Enterprise Valuekr132.32M

Total Cash (Recent Filing)kr24.85M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.08

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding72,803,314

10 Day Avg. Volume92,396

30 Day Avg. Volume134,243

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.49

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Capital Structure (no Debt)A debt-free balance sheet materially lowers solvency and interest-rate risk, giving management room to fund R&D through equity, grants, or partnerships. For an R&D-stage biotech, this preserves strategic optionality and reduces default risk over the next 2–6 months and beyond.

Platform-focused Immuno-oncology PipelineElicera’s emphasis on CAR T, oncolytic viruses and the iTANK enhancement platform provides durable technological optionality. Platform IP and multiple therapeutic modalities expand partnership and licensing pathways, supporting long-term value creation and diversified clinical development routes.

High Gross Margins When Revenue ExistedWhen sales occurred, revenue converted to near-full pass-through gross profit, indicating potentially attractive unit economics. If commercial or partnered programs scale, revenue growth could translate efficiently into operating leverage and margin expansion over a multi-quarter horizon.

Bears Say

Persistent Operating And Net LossesSustained operating and net losses erode capital and require ongoing external funding. Continued unprofitability increases dilution risk and constrains reinvestment into pivotal trials, making execution and program continuity dependent on successful financing or partnerships over the next 2–6 months.

Weak Cash Generation And Cash BurnConsistent negative operating and free cash flow means the company cannot self-fund development and is reliant on capital markets or partners. Variable cash burn complicates planning and can force program prioritization or delays if financing conditions tighten, raising execution risk.

Shrinking Equity And Volatile RevenueMaterial equity depletion reduces the balance-sheet buffer available for clinical spend and increases likelihood of dilutive raises. Revenue volatility, including zero revenue in 2025, weakens commercial visibility and partner confidence, heightening funding and execution risk for upcoming milestones.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr2.25 and its highest was kr8.21 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr180.55M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 68 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -kr0.102 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.102.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 72,803,314 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -kr0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -32.414%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.